Dr. Zac Cox discusses the ADVOR trial with co-host, Dr. Tracy Macaulay.
0:00-0:55: Introduction
0:56-4:58: ADVOR trial overview
4:59-06:51: Overall thoughts
06:52-09:39: The exclusion of SGLT2 inhibitor use
09:40-10:57: Baseline medical therapy
10:58-16:00: Congestion score
16:01-28:45: Sample size and other considerations for application
28:46-31:13: Final thoughts and Acetazolamide Trivia!
31:14-31:55: Closing
References:
ADVOR
Mullens W, Dauw J, Martens P, et al. Acetazolamide in Acute Decompensated Heart Failure with Volume Overload. N Engl J Med. 2022;387(13):1185-1195. doi:10.1056/NEJMoa2203094
DOSE
Felker GM, Lee KL, Bull DA, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011;364(9):797-805. doi:10.1056/NEJMoa1005419
CARESS HF
Bart BA, Goldsmith SR, Lee KL, et al. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med. 2012;367(24):2296-2304. doi:10.1056/NEJMoa1210357
ROSE AHF
Chen HH, Anstrom KJ, Givertz MM, et al. Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial. JAMA. 2013;310(23):2533-2543. doi:10.1001/jama.2013.282190
The 3T Trial
Cox ZL, Hung R, Lenihan DJ, Testani JM. Diuretic Strategies for Loop Diuretic Resistance in Acute Heart Failure: The 3T Trial. JACC Heart Fail. 2020;8(3):157-168. doi:10.1016/j.jchf.2019.09.012
CardioScripts 